Physician profile
Hanson T Lee
NPI 1730181116
$2,488.23
in general payments reported to CMS, 2019-2025
23 companies · $933 in 2025
The $933 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.49 · 2021: $50.92 · 2022: $321 · 2023: $573 · 2024: $543 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.27 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.97 | 2019-2025 | |
| Janssen Biotech, INC. | $351.72 | 2022-2025 | Stelara, Tremfya |
| Ironwood Pharmaceuticals, INC | $298.22 | 2022-2023 | Linzess |
| Amgen INC. | $241.63 | 2024-2025 | Krystexxa |
| Madrigal Pharmaceuticals | $191.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $176.67 | 2023-2024 | Ibsrela |
| Vivus LLC | $85.62 | 2022-2025 | Pancreaze |
| Genzyme Corporation | $76.51 | 2022 | |
| Pfizer INC. | $55.26 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $53.52 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $51.13 | 2025 | Wegovy |
| Boston Scientific Corporation | $50.42 | 2025 | Overstitch Endoscopic Suturing System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.58 | 2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $28.03 | 2023 | Dupixent |
| Gilead Sciences, INC. | $26.76 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.49 | 2019 | |
| Intercept Pharmaceuticals, INC. | $24.57 | 2025 | |
| Nestle Healthcare Nutrition INC. | $23.80 | 2023 | |
| Phathom Pharmaceuticals, INC. | $23.74 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $23.57 | 2024 | |
| Capsovision, INC. | $23.11 | 2025 | Capsocam Plus |
| Omeros Corporation | $18.30 | 2019 | |
| Intra-Sana Laboratories | $17.60 | 2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanson Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.